|
Intravenous immunoglobulin for suspected or proven infection in neonates
|
| bet | 303/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
| Intravenous immunoglobulin for suspected or proven infection in neonates: The results of the INIS trial, which enrolled 3493 infants, and meta-analyses (n = 3973) showed no reduction in mortality during hospital stay or death or major disability at two years of age. Although based on a small sample size (n = 266), IgM-enriched IVIg does not significantly reduce mortality during hospital stay in infants with suspected infection.
Routine administration of IVIg or IgM-enriched IVIg to prevent mortality in infants with suspected or proven neonatal infection is not recommended.[7] (LOE I, GOR A)
Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infants: IVIg administration results in a 3% reduction in sepsis and a 4% reduction in one or more episodes of any serious infection but is not associated with reductions in other clinically important outcomes, including mortality. Prophylactic use of IVIg is not associated with any short-term serious side effects. The decision to use prophylactic IVIg will depend on the costs and the values assigned to the clinical outcomes.[8] (LOE I, GOR B)
|
| |
